NF2 and neoplasm: Additional biomarkers can be multiplexed to create multivariate heterogeneity indices for schwannoma that could be mapped to both tumor behavior (ie growth rate or nerve dysfunction) and therapeutic response, with the ultimate goals of predicting tumor behavior, guiding treatment strategy, and improving therapeutic options for sporadic schwannoma and particularly NF2 patients, for whom few options exist.